References
- FitzmauriceCAllenCBarberRMA systematic analysis for the global burden of disease studyJAMA Oncol20173452454827918777
- KumarakulasingheNBvan ZanwijkNSooRAMolecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC)Respirology201520337037825689095
- AhnJMChoJYCurrent serum lung cancer biomarkersJ Mol Biomark Diagn2013S4001
- KemalYYucelIEkizKElevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosisAsian Pac J Cancer Prev20141562651265424761879
- BottaCBarbieriVCilibertoDSystemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patientsCancer Biol Ther201314646947523760488
- KosFTHocazadeCKosMAssessment of prognostic value of “neutrophil to lymphocyte ratio” and “prognostic nutritional index” as a sytemic inflammatory marker in non-small cell lung cancerAsian Pac J Cancer Prev20151693997400225987075
- WuGYaoYBaiCCombination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patientsThorac Cancer20156327528726273373
- YaoYYuanDLiuHGuXSongYPretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapyCancer Immunol Immunother201362347147922986452
- LeeYKimSHHanJYKimHTYunTLeeJSEarly neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapyJ Cancer Res Clin Oncol2012138122009201622772951
- ZhangHZhangLZhuKPrognostic significance of combination of preoperative platelet count and neutrophil-lymphocyte ratio (COP-NLR) in patients with non-small cell lung cancer: based on a large cohort studyPLoS One2015105e012649625950176
- LinGNPengJWXiaoJJLiuDYXiaZJPrognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doubletMed Oncol20143177024927957
- ZhaoQTYangYXuSPrognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including 7,054 patientsOnco Targets Ther201582731273826491346
- LinGNPengJWLiuPPLiuDYXiaoJJChenXQElevated neutrophil to lymphocyte ratio predicts poor outcome in patients with advanced non-small cell lung cancer receiving first-line gefitinib or erlotinib treatmentAsia Pac J Clin Oncol2014
- DingPNRobertsTLChuaWClinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health DistrictIntern Med J201747121405141128742280
- MeriggiFCodignolaCBerettaGDSignificance of neutrophil-to-lymphocyte ratio in Western advanced EGFR-mutated non-small cell lung cancer receiving a targeted therapyTumori2017103544344828731495
- MinamiSOgataYIharaSYamamotoSKomutaKNeutrophil-to-lymphocyte ratio predicts overall survival of advanced non-small cell lung cancer harboring mutant epidermal growth factor receptorWorld J Oncol20178618018729317963
- ChenY-MLaiC-HChangH-CBaseline and trend of lymphocyte-to-monocyte ratio as prognostic factors in epidermal growth factor receptor mutant non-small cell lung cancer patients treated with first-line epidermal growth factor receptor tyrosine kinase inhibitorsPLoS One108e0136252
- SimSHBeomSHAhnYOPretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitorsThorac Cancer20167216116627042217
- EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
- Uribe-QuerolERosalesCNeutrophils in cancer: two sides of the same coinJ Immunol Res201520159836982126819959